Promising Preclinical Data Support TPC-026 as a Novel Chronic Therapy for Metabolic Disorders Including Obesity
PR Newswire —
COPENHAGEN, Denmark, Jan. 28, 2026 /PRNewswire/ -- TETRAPHARM, a Copenhagen-based biopharmaceutical company focused on neuroscience, psychiatry, and metabolic disorders, today announced promising preclinical data for TPC-026, a novel investigational compound being developed for the...